Role and significance of p53 insights into breast cancer progression and therapeutic strategies: A review
DOI:
https://doi.org/10.56511/JIPBS.2020.v7.i03.pp13-20Abstract
Breast cancer is the most widespread malignancy among women worldwide, with more than one million new cases analyzed every year. The TP53 (p53) gene is mutated in about 20 to 40% of breast cancer cases, contingent upon the size of the tumor and the stage of the disease. This is an early event in the advancement of breast tumors. Several mutations of the TP53 gene have been discovered and their role in the risk of breast cancer and their association with other genetic targets for cancer development has been discussed. The role of the TP53 mutation as a prognostic marker and the role of mutated p53 participation rate in the therapeutic response were discussed. All information available in the examination of TP53 mutations in breast cancer in humans confirms the significant role of TP53 in carcinogenesis of breast cancer. In addition, reviewed therapeutic targets and treatment options discussed may also contribute to the future treatment of breast cancer.
Keywords:
Breast cancer, p53, TP53, loss of heterozygosity, gene expression profiling, therapeutic targets of TP53Downloads
References
Curado MP. Breast cancer in the world: incidence and mortality. Salud Pública de México. 2011; 53: 372-84.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L. Siegel MPH, Lindsey A. Torre MSPH, Ahmedin Jemal. Global cancer statistics: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018; https://doi.org/10.3322/caac.21492.
International Agency for Research on Cancer, World Health Organization: PRESS RELEASE N° 263, 2018.
Geoffrey M Cooper. The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): Sinauer Associates. 2000; ISBN-10: 0-87893-1066.
Tracey A. Martin, Lin Ye, Andrew J. Sanders, Jane Lane, and Wen G. Jiang. Cancer Invasion and Metastasis: Molecular and Cellular Perspective. Landes Bioscience. 2013.
Cancer Facts & Figures. American cancer society, 2019.
Lee EY, Muller WJ. Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol. 2010; doi: 10.1101/cshperspect.a003236.
Noa Rivlin, Ran Brosh, Moshe Oren, Varda Rotter. Mutations in the p53 Tumor Suppressor Gene Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer. 2011; 2(4): 466 – 474.
Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010; 2(1): doi: 10.1101/cshperspect.a001008.
Zhou W, Muggerud AA, Vu P, Due EU, Sørlie T, Børresen-Dale AL, Wärnberg F, Langerød A. Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution. Mol Oncol. 2009; 3(3):214-9.
Duffy MJ, Synnott NC, Crown J. Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Res Treat. 2018; 170(2):213-219.
Hortobagyi G.N, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis C.A, Khaled H, Liu M.C, Martin M, Namer M, O'Shaughnessy J.A, Shen Z.Z, Albain K.S. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005; 6:391 -401.
Breast Cancer Facts & Figures 2017-2018. American Cancer Society, Inc. 2017.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424.
Robles SC, Galanis E. Breast cancer in Latin America and the Caribbean. Rev Panam Salud Publica. 2002; 11(3):178-85.
Biplob Dey, Arun Kumar. A Review Article on Breast Cancer. International journal of pharmacy and pharmaceutical sciences 2018; 11(2): 284-298.
Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, Tse GM, Badve S, Ellis IO. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010; 12(4): 207.
Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they?. Mol Oncol. 2010; 4(3):192-208.
Makki J. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin Med Insights Pathol. 2015; 8:23-31.
Hanby A.M, walker C. Tavassoli FA, Devilee P: Pathology and Genetics: Tumours of the Breast and Female Genital Organs. WHO Classification of Tumours series - volume IV. Lyon, France: IARC Press. Breast Cancer Res. 2004; (6): 133.
Viale G, Mastropasqua M.G. What can the pathologist offer for optimal treatment choice?. Ann Oncol. 2010; 21: vii27-29.
Chen C, Yuan J, Wei W, Tu Y, Yao F, Yang X.Q, Sun J.Z, Sun S.R, Li Y. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications. Int J Nanomedicine. 2014; 9: 1039-1048.
Song Q, Merajver SD, Li JZ. Cancer classification in the genomic era: five contemporary problems. Hum Genomics. 2015; 9:27.
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98(4): 262-72.
Arpino G, Generali D, Sapino A, Del Matro I, Frassoldati A, de Laurentis M, Paolo P, Mustacchi G, Cazzaniga M, De Placido S, Conte P, Cappelletti M, Zanoni V, Antonelli A, Martinotti M, Puglisi F, Bemti A, Bottini A, Doglioni L. Gene expression profiling in breast cancer: a clinical perspective. Breast. 2013; 22:109-120.
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, Shi B. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015; 5(10): 2929-43.
Tarca AL, Romero R, Draghici S. Analysis of microarray experiments of gene expression profiling. Am J Obstet Gynecol. 2006; 195(2):37388.
Malvia S, Bagadi SAR, Pradhan D, Chintamani C, Bhatnagar A, Arora D, Sarin R, Saxena S. Study of Gene Expression Profiles of Breast Cancers in Indian Women. Sci Rep. 2019; 9(1): 10018.
Hamzehloie T, Mojarrad M, Hasanzadeh Nazarabadi M, Shekouhi S. The role of tumor protein 53 mutations in common human cancers and targeting the murine double minute 2-p53 interaction for cancer therapy. Iran J Med Sci. 2012; 37(1): 3-8.
Berger MF, Garraway LA. Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am. 2009; 23(3):397414.
Rodriguez-Esteban R, Jiang X. Differential gene expression in disease: a comparison between high-throughput studies and the literature. BMC Med Genomics. 2017; 10(1):59.
Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G, Print C. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol. 2010; 2(2):125-48.
Hand DJ, Heard NA. Finding groups in gene expression data. J Biomed Biotechnol. 2005; (2):215-25.
De Silva S, Tennekoon KH, Karunanayake EH. Overview of the genetic basis toward early detection of breast cancer. Breast Cancer (Dove Med Press). 2019; 11:71-80.
Ozaki T, Nakagawara A. Role of p53 in Cell Death and Human Cancers. Cancers (Basel). 2011; 3(1):994-1013.
Murnyák B, Hortobágyi T. Immunohistochemical correlates of TP53 somatic mutations in cancer. Oncotarget. 2016; 7(40):64910-64920.
Chang F, Syrjänen S, Kurvinen K, Syrjänen K. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol. 1993; 88(2):174-86.
Hamzehloie T, Mojarrad M, Hasanzadeh Nazarabadi M, Shekouhi S. The role of tumor protein 53 mutations in common human cancers and targeting the murine double minute 2-p53 interaction for cancer therapy. Iran J Med Sci. 2012; 37(1): 3-8.
Slee E. A, Connor D. J. O, Lu X. “To die or not to die: how does p53 decide?”. Oncogene. 2004; 23(16): 2809 -2818.
Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 2004; 4:793-805.
Pflaum J, Schlosser S, Müller M. p53 Family and Cellular Stress Responses in Cancer. Front Oncol. 2014; 4:285.
Børresen-Dale AL. TP53 and breast cancer. Hum Mutat. 2003; 21(3): 292-300.
Trimble EL, Ungerleider RS, Abrams JA, Kaplan RS, Feigal EG, Smith MA, Carter CL, Friedman MA. Neoadjuvant therapy in cancer treatment. 1993; 72(11): 3515-24.
Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlböck M, Gnant M, Steger G, Jakesz R. TP53 Mutation and p53 Overexpression for Prediction of Response to Neoadjuvant Treatment in Breast Cancer Patients. Clinical Cancer Research. 2000; (6):50-56.
Mustapha Abubakar , Changyuan Guo , Hela Koka , Hyuna Sung, Nan Shao, Jennifer Guida, Joseph Deng, Mengjie Li, Nan Hu, Bin Zhou, Ning Lu, Xiaohong R. Yang. Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression. npj Breast Cancer. 2019; 5: 20.
Ljungman M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia. 2000; 2(3): 208-25.
Stegh AH. Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils. Expert Opin Ther Targets. 2012; 16(1):67-83.
Joerger AC, Fersht AR. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. Annu Rev Biochem. 2016; 85:375-404.
Kim HG, Hwang SY, Aaronson SA, Mandinova A, Lee SW. DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation. J Biol Chem. 2011; 286(20): 17672-81.
Tanaka T, Watanabe M, Yamashita K. Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. Oncotarget. 2018; 9(22): 16234-16247.
Robles AI, Jen J, Harris CC1. Clinical Outcomes of TP53 Mutations in Cancers. Cold Spring Harb Perspect Med. 2016; 6(9): a026294.
Berge EO, Huun J, Lillehaug JR, Lønning PE, Knappskog S. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. Biochim Biophys Acta. 2013; 1830(3):2790-7.
Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007; 9(3):R30.
Denisenko TV, Pivnyuk AD, Zhivotovsky B. p53-AutophagyMetastasis Link. Cancers (Basel). 2018; 10(5). pii: E148.
Wang Z, Sun Y. Targeting p53 for Novel Anticancer Therapy. Transl Oncol. 2010; 3(1):1-12.
Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol. 2010; 2(9): a001222.
Powell E, Piwnica-Worms D, Piwnica-Worms H. Contribution of p53 to metastasis. Cancer Discov. 2014; 4(4):405-14.
Blandino G, Di Agostino S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. 2018; 37(1):30.
Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer biology & therapy. 2010; 10(10):955-60.
Published
How to Cite
Issue
Section
Copyright (c) 2020 Umadevi Bommu, Suneetha Yeguvapalli
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at